P-OGC92 Esophagogastric Lymphomas; Lymphomas outside Lymphoid tissue. (16th December 2021)

• Record Type: Journal Article
• Authors: Younus, Hafsa; Thomas, Joel Joy; Siddiq, Faateh; Sharma, Vishali; Fiyyaz, Sadaf; Mukherjee, Dipankar; Mukherjee, Samrat
• Is Part Of: British journal of surgery. Volume 108:Supplement 9(2021)
• Publication Date: 2021-12-16
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znab430.219
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Background: Primary gastric lymphomas are rare tumours and account for 5% of all gastric neoplasms. Esophaphageal lymphomas are even rarer, accounting for 1% of all oesophageal tumours. Incidence of these tumours have been increasing over time and there is increasing need to understand this tumour subtype. This is a single centre study of esophagogastric lymphomas over a period of 15 years. Methods: Between 2005 to 2020; patients who were diagnosed of having esophagogastric lymphomas, were retrospectively studied. Their clinical records were assessed for age, gender, clinical signs and symptoms, histological type, association with H pylori, LDH levels, stage at diagnosis, treatment type, Endoscopy and clinical follow up and survival. Results: 66 patients were diagnosed of having lymphoma, out of which 4 (6%) were oesophageal and 62 (93.93%) were gastric. Median age was 77 years (Range 41-102 years), 39 were male (59%) and 27(41%) were female. Anaemia was the commonest sign (53%), followed by nausea/vomiting (45%), weight loss (44.5%), abdominal pain (40.6%) and dysphagia (24%). 15.6% patients were found to have H pylori and 10% of patients had Barrett's. Diffuse Large B Cell Lymphomas were commonest tumours (28.33%) followed by MALToma's (26.6%). 60% patients were T3/4 at the time of diagnosis and 9.7% had other OG malignancies. 53% patients received antibiotics, 61% received chemotherapy, 16% received chemoradiotherapy and 16% received surgical resection. Median survival was 3 years (range 0-14). Conclusions: Esophagogastric lymphomas are successfully treated with chemotherapy with promising survival. The stage at diagnosis and presence of comorbidities are limiting factors in overall disease prognosis.